Key result
Factor Xa inhibitors cut recurrent VTE risk ~35% vs LMWH in cancer patients.
Why the study?
The bleeding risk associated with Factor Xa inhibitors compared to low molecular weight heparin in patients with cancer-associated venous thromboembolism remains ambiguous and concerning.
Do Factor Xa inhibitors reduce recurrent VTE compared to LMWH in patients with cancer-associated VTE?
Meta-Analysis (n=17,781)
Do Factor Xa inhibitors reduce recurrent VTE compared to LMWH in patients with cancer-associated VTE?
Factor Xa inhibitors are an effective alternative to LMWH for cancer-associated VTE, significantly reducing VTE recurrence but with an increased risk of bleeding.
Answers are grounded in this paper and cite their sources.
Supports Factor Xa inhibitors over LMWH for cancer-associated VTE; confirms reduced recurrence across randomized trials.
Background Patients with cancer-related venous thromboembolism (CA-VTE) have discovered Factor Xa inhibitors to be an effective intervention in recent decades. However, the greater bleeding risk involved with Factor Xa inhibitors than with low molecular weight heparin (LMWH) has now been substantiated in non-randomized studies as well as randomized control trials (RCT), albeit ambiguously, and this raises concerns for patients with CA-VTE. Aims We aim to pool data from all relevant studies reporting results for recurrent VTE, bleeding and mortality related to bleeding in CA-VTE patients undergoing treatment with Factor Xa inhibitors versus LMWH. Methods PubMed and Scopus databases were queried from inception through last week of March, 2022 for all RCT and non-randomized studies comparing the efficacy of Factor Xa inhibitors versus LMWH in patients with CA-VTE, on recurrence of VTE, clinically relevant non-major bleeding (CRNMB) and major bleeding events and mortality related to bleeding. A random-effects model was used and risk ratios (RR) with 95% confidence intervals (CI) were reported. Results Fourteen non-randomized studies and six RCTs were included in our analysis. The total participants were 17,781. Our pooled analysis demonstrated that in non-randomized studies, Factor Xa inhibitors, compared to LMWH, had a significantly lower risk of recurrence of VTE (RR: 0.70 [0.60, 0.80]; p = 0.00001; I2 = 0%) and a significantly higher risk of overall bleeding (RR: 1.51 [1.10, 2.07]; p = 0.01; I2 = 59%), however, no significant difference in the risk of bleeding-related mortality was observed between Xa inhibitors and LMWH (RR: 0.99 [0.34, 2.92]; p = 0.99; I2 = 0%). In RCTs, Factor Xa inhibitors, compared to LMWH, had a significantly lower risk of recurrence of VTE (RR: 0.65 [0.49, 0.85]; p = 0.002; I2 = 3%) and a significantly higher risk bleeding (RR: 1.35 [1.02, 1.80]; p = 0.04; I2 = 37%). However, no significant difference in the risk of bleeding-related mortality was observed between Factor Xa inhibitors and LMWH (RR: 0.33 [0.07, 1.43]; p = 0.14; I2 = 0%). Furthermore, our pooled analysis demonstrated that there was no significant difference in the risk of overall bleeding in GI malignancies, between Factor Xa inhibitors and LMWH (RR: 1.39 [0.86, 2.26]; p = 0.18; I2 = 58%), risk of CRNMB (RR: 1.52 [0.80, 2.88]; p = 0.20; I2 = 56%), and the risk of major bleeding (RR: 1.29 [0.66, 2.48]; p = 0.46; I2 = 46%). Conclusion Our results show that in the context of CA-VTE, Factor Xa inhibitor therapy may be a safe, effective, and realistic alternative to LMWH.
No takes yet. Share an insight, caveat, or question.
Qurashi et al. (2022) conducted a meta-analysis in Cancer-associated venous thromboembolism (CA-VTE) (n=17,781). Factor Xa inhibitors vs. Low molecular weight heparin (LMWH) was evaluated on Recurrence of venous thromboembolism (RCT pooled analysis) (RR 0.65, 95% CI 0.49, 0.85, p=0.002). In randomized controlled trials, Factor Xa inhibitors reduced the risk of recurrent venous thromboembolism compared to low molecular weight heparin in patients with cancer.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: